文献速递药物不良反应与药物警戒

加拿大行政数据诊断编码识别药物不良事件验证研究

Validating use of diagnostic codes in Canadian administrative data for identification of adverse drug events.
PubMed 文献 · Br J Clin Pharmacol · 2024-04-11

结果显示1178例确诊事件中,编码敏感度仅3.4%至52.6%,剂量相关事件和不依从事件的记录更差,提示行政数据对药物不良事件的捕获能力有限。

要点

  • 行政数据诊断编码识别药物不良事件的敏感度范围为3.4%至52.6%,取决于数据库和编码方案。
  • 剂量相关事件(OR 0.32,95%CI 0.15–0.69)和不依从事件(OR 0.35,95%CI 0.20–0.62)在行政数据中记录更差。
  • 发生心律失常的事件记录更好(OR 4.19,95%CI 0.96–18.28)。

核心结论

  • 药物不良事件在行政数据中记录不佳,敏感度低至3.4%至52.6%。
  • 应考虑替代方法捕获药物不良事件以用于健康研究。

研究设计与样本

  • 将前瞻性识别的药物不良事件与行政保险数据链接,评估不同诊断编码方案的敏感度和特异度。
  • 采用逻辑回归分析事件特征与行政数据记录质量的关联。

主要发现

  • 1178例确诊事件中,诊断编码敏感度范围为3.4%至52.6%,取决于数据库和编码方案。
  • 剂量相关事件记录更差(OR 0.32,95%CI 0.15–0.69)。
  • 不依从事件记录更差(OR 0.35,95%CI 0.20–0.62)。
  • 心律失常事件记录更好(OR 4.19,95%CI 0.96–18.28)。

临床怎么用

  • 临床药学智能体在利用行政数据识别药物不良事件时应了解其敏感度有限,不宜单独依赖诊断编码。
  • 对剂量相关事件和不依从事件需结合其他数据源主动监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: While diagnostic codes from administrative health data might be a valuable source to identify adverse drug events (ADEs), their ability to identify unintended harms remains unclear. We validated claims-based diagnosis codes for ADEs based on events identified in a prospective cohort study and assessed whether key attributes predicted their documentation in administrative data. METHODS: This was a retrospective analysis of 3 prospective cohorts in British Columbia, from 2008 to 2015 (n = 13 969). We linked prospectively identified ADEs to administrative insurance data to examine the sensitivity and specificity of different diagnostic code schemes. We used logistic regression to assess which key attributes (e.g., type of event, symptoms and culprit medications) were associated with better documentation of ADEs in administrative data. RESULTS: Among 1178 diagnosed events, the sensitivity of the diagnostic codes in administrative data ranged from 3.4 to 52.6%, depending on the database and codes used. We found that documentation was worse for certain types of ADEs (dose-related: odds ratio [OR]: 0.32, 95% confidence interval [CI]: 0.15, 0.69; nonadherence events (OR: 0.35, 95% CI: 0.20, 0.62), and better for those experiencing arrhythmias (OR: 4.19, 95% CI: 0.96, 18.28). CONCLUSION: ADEs were not well documented in administrative data. Alternative methods should be explored to capture ADEs for health research.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Wickham ME, McGrail KM, Law MR, et al. Validating use of diagnostic codes in Canadian administrative data for identification of adverse drug events. Br J Clin Pharmacol. 2024. PMID: 38604986. doi:10.1111/bcp.16067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。